Data as of Oct 24
| -0.016 / -5.35%|
Hemispherx Biopharma, Inc. is a biopharmaceutical company, which engages in treating and preventing chronic viral and immune-based disorders through the development and manufacturing of compounds that enhance the natural immune system of the human body. Its products include Alferon N Injection and the experimental immunotherapeutic/antiviral Ampligen. Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. Ampligen includes application as a treatment for Chronic Fatigue Syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Philadelphia, PA.
|William A. Carter||Chairman, President, Chief Executive Officer & CSO|
|Wayne S. Springate||Senior Vice President-Operations|
|Thomas Kenwood Equels||Executive Vice Chairman, CFO & Secretary|
|David R. Strayer||CMO, Medical Director & Head-Regulatory Affairs|
|Ralph Christopher Cavalli||Vice President-Quality Control|